Please assess the completion status of the following clinical trial:

Trial Title: Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between the age of 18 to 75 years~* Subjects with end stage renal disease (CKD stage 5) on hemodialysis and on epoetin treatment for at least 3 months prior to screening~* Subjects with haemoglobin between 10 g/dl to 12 g/dl~* Subjects who are on clinically stable haemodialysis (defined as no clinically relevant changes of dialysis regimen and/or dialyzer) for at least 3 months prior to screening~* Subjects willing to provide a written informed consent~* Subjects with serum ferritin ≥ 200 μg/L and/or transferrin saturation ≥ 20%~* Subjects with a life expectancy of more than at least study period in clinical judgment of the investigator~Exclusion Criteria:~* Subjects with anaemia due to other reasons (that is not renal anaemia)~* Subjects who have undergone blood transfusion within the last 3 months~* Subjects with major complication such as severe/chronic infections or bleeding or aluminum toxicity~* Subjects with suspected or known pure red cell aplasia (PRCA)~* Subjects with a history of aplastic anaemia~* Subjects with uncontrolled diabetes (fasting blood glucose \> 240 mg/dl) or uncontrolled hypertension (systolic blood pressure \> 180 mm Hg, diastolic blood pressure \> 110 mm Hg)~* Subjects with known hypersensitivity to any of the ingredients of the investigational products, the mammalian cell-derived product or human albumin products~* Subjects with history of seizure disorder~* Subjects with hematological disorder~* Subjects with hyperparathyroidism~* Subjects with congestive heart failure and/or angina (NYHA class III and IV)~* Subjects with myocardial infarction or stroke in the preceding 6 months of screening~* Subjects with active malignancy in the previous 5 years~* Subjects with gastrointestinal bleeding in the past 6 months~* Subjects with immunosuppressive therapy in the previous 3 months~* Subjects with active hepatitis B virus (HBsAg) (positive for HBsAg and IgM anti-HBc) and hepatitis C virus (HCV) (positive for Anti-HCV antibody) and human immunodeficiency virus (HIV)~* Female subjects who are pregnant, breast-feeding, planning to be pregnant during the study, or women of child-bearing potential (any woman who is not surgically sterile i.e. bilateral tubal ligation, total hysterectomy or \< 2 years post menopause) not using a reliable method of double contraception (e.g. condom plus diaphragm, condom or diaphragm plus spermicidal gel/foam, tubal ligation, or stable dose of hormonal contraception) throughout the study period~* Subjects participating in trials involving erythropoietin in the past 6 months before screening.Subjects currently participating or participation in an investigational study within 30 days prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Reference group (Type: ACTIVE_COMPARATOR): Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks.
- Experimental group (Type: EXPERIMENTAL): Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).